title: Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilization survey.
authors.forename: Laurent
authors.initials: L
authors.lastname: Sailler
authors.forename: Camille
authors.initials: C
authors.lastname: Attane
authors.forename: Fleur
authors.initials: F
authors.lastname: Michenot
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Canonge
authors.forename: Lionel
authors.initials: L
authors.lastname: Rostaing
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Arlet-Suau
authors.forename: Philippe
authors.initials: P
authors.lastname: Arlet
authors.forename: François
authors.initials: F
authors.lastname: Launay
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Montastruc
authors.forename: Maryse
authors.initials: M
authors.lastname: Lapeyre-Mestre
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D004348:Drug Labeling; D005260:Female; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects; D007155:Immunologic Factors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab